$CATX

Lantheus Holdings, Inc. sold $112K of CATX

Lantheus Holdings, Inc. sold 35,769 shares of Perspective Therapeutics, Inc. (CATX) at $3.12 ($0.11M total) on 2026-09-01.

Original reporting
SEC EDGAR · Lantheus Holdings, Inc.
Published Sep 3, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CATX
Neutral
high confidence
Mentioned
$CATX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CATXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Primary disclosure of a small insider sell; low trading relevance.

03

What to watch

The insider remains a 10% owner; the sale represents less than 0.3% of holdings.

Relevance 4/10Novelty 4/10Timing: filing Sep 3, 2026

Background

SEC Form 4 filing reports an insider transaction for Perspective Therapeutics.

Company-level read

Ticker impact

$CATXNeutralHigh confidence
Context

Form 4 disclosed Lantheus sold 35,769 shares of Perspective Therapeutics for $111.6K on Sep 1, 2026.

Expected impact

Potential modest dip or flat price action.

Evidence & confidence

Sale size is small relative to total holdings and market cap; no 10b5-1 plan indicates discretionary sale.

Market effects

Limited impact on the biotech sector.

No regional market effect.

Not globally material.

Counterpoint

Despite the small sale, some traders may view any insider sell as a bearish signal.

Key entities

  • Perspective Therapeutics, Inc.

    Biotech firm (NASDAQ: CATX) whose insider sold shares.

  • Lantheus Holdings, Inc.

    Reporter of the Form 4, holding a 10% stake.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CATXMed

Perspective Therapeutics, Inc. (CATX): Results of Operations and Financial Condition

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 s